首页> 外文OA文献 >Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas

【2h】

Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas

机译：Stat3靶向疗法克服了对黑素瘤对维拉非尼的获得性耐药

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Liu Fang; Cao Juxiang; Wu Jinxiang; Sullivan Kayleigh; Shen James; Ryu Byungwoo; Xu Zhixiang; Wei Wenyi; Cui Rutao;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 通过非靶向代谢组学和稳定同位素示踪技术分析索拉非尼耐药白血病细胞的代谢重编程和氧化还原适应 [J] . 游昕, 胡寓旻, 姜伟业, 癌症（英文版） . 2020,第007期
2. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas [J] . LiuF., CaoJ., WuJ., The Journal of investigative dermatology. . 2013,第8期

机译：Stat3靶向疗法克服了黑色素瘤对维拉非尼的获得性耐药
3. Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF(V600E) Melanoma [J] . Wang Jin, Chen Jianjun, Miller Duane D., Molecular cancer therapeutics . 2014,第1期

机译：新型微管蛋白抑制剂ABI-274和Vemurafenib的协同组合克服了BRAF（V600E）黑色素瘤获得Vemurafenib的耐药性
4. Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF(V600E) Melanoma [J] . Wang Jin, Chen Jianjun, Miller Duane D., Molecular cancer therapeutics . 2014,第1期

机译：新型微管蛋白抑制剂ABI-274和Vemureafenib的协同组合克服了BRAF（V600E）黑色素瘤的抗脓尿嘧啶
5. Overcoming Acquired Resistance in BRAFV600 Melanoma Using a Combination of ABI-274 and Vemurafenib in a Predictive A375RF21Model [C] . Wei Li, Jin Wang, Jianjun Chen, Molecular Medicine TRI-CON. . 2014

机译：使用ABI-274和VemureaFenib的组合在预测A375RF21MODEL中克服BRAF V600黑素瘤的耐受性
6. Novel Combination Therapy to Overcome Adaptive and Acquired MAPK-inhibitor Resistance in Melanoma [D] . Hong, Aayoung 2016

机译：新型的组合疗法，克服黑色素瘤的适应性和获得性MAPK抑制剂耐药性
7. Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma [O] . Jin Wang, Jianjun Chen, Duane D. Miller, -1

机译：新型微管蛋白抑制剂ABI-274和Vemurafenib的协同结合克服了BRAFV600E黑色素瘤中Vemurafenib获得性耐药
8. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma [O] . Atul Kulkarni, Husam Al-Hraishawi, Srilatha Simhadri, 2017

机译：BRAF融合作为BRAFV600E突变体黑素瘤的vemureafenib的一种新机制
9. Acquired Tamoxifen Resistance and Overexpression of Anti-Apoptotic Molecules: A Potential Strategy for Overcoming Endocrine Resistance [R] . Lippman, M. , Xu, L. 2005

机译：获得的他莫昔芬抗性和抗凋亡分子的过度表达：克服内分泌抗性的潜在策略

Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas

著录项

引文网络

相似文献

相关主题

期刊订阅